$11.15
8.12% today
Nasdaq, Apr 04, 08:47 pm CET
ISIN
US18507C1036
Symbol
CLPT
Sector

ClearPoint Neuro Stock price

$12.14
-1.42 10.44% 1M
+1.02 9.13% 6M
-3.25 21.10% YTD
+5.54 83.86% 1Y
+0.86 7.58% 3Y
+8.86 269.97% 5Y
+8.14 203.38% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.96 7.30%
ISIN
US18507C1036
Symbol
CLPT
Sector

Key metrics

Market capitalization $335.32m
Enterprise Value $318.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.16
P/S ratio (TTM) P/S ratio 10.68
P/B ratio (TTM) P/B ratio 13.20
Revenue growth (TTM) Revenue growth 31.04%
Revenue (TTM) Revenue $31.39m
EBIT (operating result TTM) EBIT $-19.75m
Free Cash Flow (TTM) Free Cash Flow $-9.23m
Cash position $20.10m
EPS (TTM) EPS $-0.70
P/E forward negative
P/S forward 8.77
EV/Sales forward 8.34
Short interest 2.77%
Show more

Is ClearPoint Neuro a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

ClearPoint Neuro Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a ClearPoint Neuro forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a ClearPoint Neuro forecast:

Buy
100%

Financial data from ClearPoint Neuro

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
31 31
31% 31%
100%
- Direct Costs 12 12
19% 19%
39%
19 19
40% 40%
61%
- Selling and Administrative Expenses 25 25
7% 7%
78%
- Research and Development Expense 12 12
6% 6%
39%
-18 -18
15% 15%
-57%
- Depreciation and Amortization 1.90 1.90
30% 30%
6%
EBIT (Operating Income) EBIT -20 -20
12% 12%
-63%
Net Profit -19 -19
14% 14%
-60%

In millions USD.

Don't miss a Thing! We will send you all news about ClearPoint Neuro directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ClearPoint Neuro Stock News

Positive
Seeking Alpha
about one month ago
ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical services should provide the drug delivery business with a boost within the next 18 months. ClearPoint also continues to control its cash burn, despite continuing to make investments in future growth.
Neutral
Seeking Alpha
about one month ago
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings.
Neutral
Accesswire
about one month ago
Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ende...
More ClearPoint Neuro News

Company Profile

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Head office United States
CEO Joseph Burnett
Employees 115
Founded 1998
Website www.clearpointneuro.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today